The Pharmacy Times® Oncology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
The study findings emphasize the need for people who missed or postponed a cancer screening test early in the pandemic to contact their health care provider to discuss the potential need to reschedule it, according to the study authors.
FDA grant priority review to a supplemental biologics license application for nivolumab (Opdivo) for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer.
Obstacles to cancer screenings for low-income patients can include lack of transportation and an inability to take time off of work.
FDA Grants Priority Review to Treatment for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Narsoplimab is an investigational, fully human IgG4 monoclonal antibody was designed to bind to mannan-binding lectin-associated serine protease-2
According to Senhwa Biosciences, the study’s findings indicate a clinically meaningful improvement in progression-free survival (PFS) (P<0.05).
FDA Fast Tracks Padeliporfin Immune Photo Activated Cancer Therapy for Upper-Tract Urothelial Cancer
A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.
The FDA approved Enhertu in January 2020 for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
Experts in the field of chronic lymphocytic management [CLL] discuss important disease-related factors to take into consideration when determining a patient’s therapy regimen.
A survey found that the majority of oncologists did not feel like they could perform their duties as well as they could prior to the COVID-19 pandemic.
Novel program found cost effective and safe for patients with cancer managing the adverse effects of treatment.
Treating Ductal Carcinoma In Situ with Surgery, Radiotherapy Offers Better Protection Than Surgery Alone
Although only a proportion of DCIS cases will progress into invasive cancer, the treatments available for DCIS are similar to treatments for invasive breast cancers.
Katie Culos, PharmD, BCOP and Daniel Wojenski, PharmD, BCPS, BCOP discuss the NCCN (National Comprehensive Cancer Center)-recommended front-line treatment options for patients with newly diagnosed CLL ([chronic lymphocytic leukemia)].